Last reviewed · How we verify
NCT06113471
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Active, enrolled
Phase 3
Last updated 31 March 2026
What this trial tests
Phase 3 trial testing Povorcitinib in NonSegmental Vitiligo in 450 participants. Participants enrolled and being followed up; not accepting new ones.
Timeline
27 November 2023
Primary endpoint
17 March 2026
17 March 2026
16 March 2027
Quick facts
| Lead sponsor | Incyte Corporation |
|---|---|
| Phase | Phase 3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 450 |
| Start date | 27 November 2023 |
| Primary completion | 17 March 2026 |
| Estimated completion | 16 March 2027 |
| Sites | 86 locations across France, Italy, United Kingdom, Germany, Hungary, Poland, Canada, Bulgaria |
Drugs / interventions tested
- Povorcitinib — full drug profile →
- Placebo
Conditions studied
- NonSegmental Vitiligo — all drugs for NonSegmental Vitiligo →
Sponsor
Incyte Corporation — full company profile →
Who can join
18 and older, any sex, with NonSegmental Vitiligo. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences.
Yamaguchi HL, Yamaguchi Y, Peeva E. · · 2025 · cited 9× · PMID 39258892 · DOI 10.1111/jdv.20311 -
Up-and-Coming Drugs for the Treatment of Vitiligo.
Seong SH, Oh SH. · · 2024 · cited 8× · PMID 39082655 · DOI 10.5021/ad.24.038 -
Emerging Therapeutic Innovations for Vitiligo Treatment.
Li W, Dong P, Zhang G, Hu J, et al · · 2025 · cited 1× · PMID 40136446 · DOI 10.3390/cimb47030191 -
The role of JAK3 and TEC family kinases in vitiligo pathogenesis.
Passeron T, Seneschal J, Picardo M, Xiang L, et al · · 2026 · PMID 41918735 · DOI 10.3389/fimmu.2026.1662245 -
Oral JΑΚ Inhibitors in Vitiligo Treatment.
Panagopoulou A, Sotiriou E, Papadimitriou I, Pavlidis A, et al · · 2026 · PMID 41559511 · DOI 10.1007/s13555-026-01652-x
Verify or expand the search:
- PubMed search for NCT06113471
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Povorcitinib
Trials testing the same drug.
- NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S · Phase 2 · recruiting
- NCT06516952 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) · Phase 3 · recruiting
- NCT06516965 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) · Phase 3 · active not recruiting
- NCT06505265 — A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healt · Phase 1 · completed
- NCT06441318 — A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants · Phase 1 · completed
Other recruiting trials for NonSegmental Vitiligo
Currently open trials in the same condition.
- NCT07437560 — Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo · Phase 2 · recruiting
- NCT06804811 — A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vit · Phase 3 · recruiting
- NCT06548360 — A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo · Phase 3 · recruiting
- NCT06113445 — A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) · Phase 3 · active not recruiting
Other Incyte Corporation trials
Trials by the same sponsor.
- NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
- NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
- NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
- NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06113471 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06113471.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing